Viking Therapeutics stock drops after hours as $400m raise follows 36% VK2735 surge
Viking Therapeutics is seeking $400 million through stock and convertible-note offerings immediately after VK2735 obesity data sent its shares sharply higher, as the company accelerates Phase 3 development and explores monthly and every-other-week maintenance dosing.